This inventor holds 3 USPTO granted patents and 6 published patent applications. Top assignees: Abbvie Inc., Genentech, Inc., Hoffmann-La Roche Inc.. Active years: 2021-2023.
Company Filing History:
3 out of 826 
3 out of 3,294 
3 out of 5,020 
Years Active: 2021-2023
Title: Andrew W Roberts: Innovator in Cancer Therapy
Introduction
Andrew W Roberts is a notable inventor based in Melbourne, Australia. He has made significant contributions to the field of cancer treatment through his innovative approaches. With a total of 3 patents, his work focuses on combination therapies that enhance the effectiveness of cancer treatments.
Latest Patents
One of his latest patents is titled "Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor." This invention is directed towards a combination therapy that involves a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for treating patients suffering from cancer, particularly those with CD20-expressing cancers. This innovative approach aims to improve patient outcomes by targeting cancer cells more effectively.
Career Highlights
Throughout his career, Andrew has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and AbbVie Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas in cancer therapy.
Collaborations
Andrew has collaborated with several professionals in his field, including Sari L Heitner Enschede and Wayne J Fairbrother. These collaborations have contributed to the advancement of his research and the development of his patents.
Conclusion
Andrew W Roberts is a distinguished inventor whose work in cancer therapy has the potential to significantly impact patient care. His innovative combination therapies represent a promising direction in the fight against cancer.